Purchase any WEBINAR and get
10% Off
CODE: SAVE10
T&C applicable, please referFAQ
Validity : 15th May'25 to 25th May'25
Review of Chemistry, Manufacturing and Controls (CMC) of an Investigational New Drug Application (IND)
- Outline of the relevance of information from the CMC perspective
- Understanding differences between small molecules and Biologics
- Glimpse of CFR 312.22 with the highlight on the FDA’s primary objectives in reviewing an IND
- Overview of Pre-IND activities
- CMC package: IND content and Format with emphasis on the Drug Substance and Drug Product
Overview of the webinar
- Outline of the relevance of information from the CMC perspective
- Understanding differences between small molecules and Biologics
- Glimpse of CFR 312.22 with the highlight on the FDA’s primary objectives in reviewing an IND
- Overview of Pre-IND activities
- CMC package: IND content and Format with emphasis on the Drug Substance and Drug Product
Who should attend?
The following professionals or disciplines will benefit from attending this Webinar:
- Regulatory affairs professionals
- Senior management executives (CEO, COO, CFO, etc)
- Drug discovery and development professionals (R&D and CMC)
- Intellectual property experts
- Project Managers and Clinical trial specialists
- Regulatory Compliance Associates and Managers
- People investing in FDA-regulated product development projects
Why should you attend?
This webinar is designed to help pharma companies through the various key aspects of the Chemistry Manufacturing and Controls (CMC) information expected by FDA in an IND (Investigational New Drug) Application. The presentation will cover the key aspects of CMC package. And will explore the individual requirements across both the Drug Substance as well as the Drug Product sections of the CMC package.
Faculty - Ms.Gowri Sukumar
Gowri Sukumar is the Director, CMC and Regulatory Affairs for Iterion Therapeutics, Houston, TX. Unique to her experience is leading all the technical disciplines of CMC development as well as regulatory Affairs. She has broad responsibilities that include process development, Drug Substance and Drug Product manufacturing from the CMC side. From the Regulatory affairs perspective, she provides regulatory leadership and expertise for regulatory strategy, liaises with the regulatory agencies including FDA, Health Canada and other Health authorities. For her leadership approach, she brings a strong focus beyond the necessary technical disciplines and regulations, looking at the interplay of culture and teamwork for successfully advancing programs in an effective and efficient manner. Gowri holds a master’s Degree in Biosciences as well as the prestigious Regulatory Affairs Certification (RAC) awarded by the Regulatory Affairs Professional Society. She is the author or co-author of several peer-reviewed research publications as well as book chapters. Gowri has breath of experience spanning R&D, CMC and Regulatory affairs. She also serves as a reviewer for several international Bioscience Journals for providing Scientific and technical expertise.